Clinical role of antiarrhythmic drugs in the prevention of sudden death

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Sudden cardiac death is a leading cause of mortality in the United States, but recent studies suggest that its annual incidence is declining. The annual incidence of sudden cardiac death is about 0.55 per 1000 people in North America, accounting for more than 160,000 deaths each year in the United States.1 In Seattle, there was a 34% decrease in the annual incidence of out-of-hospital cardiac arrest and a 56% decrease in ventricular fibrillation (VF) as the first identified rhythm between 1980 and 2000.2 This trend corresponds with the declining incidence of cardiovascular disease in this country in the past two decades.1 Holter monitoring has revealed that more than 75% of sudden cardiac deaths are due to ventricular tachycardia (VT) or VF.3 A large majority of these patients have underlying structural heart disease including dilated and hypertrophic cardiomyopathies and ischemic heart disease.

Original languageEnglish (US)
Title of host publicationElectrical Diseases of the Heart: Genetics, Mechanisms, Treatment, Prevention
PublisherSpringer London
Pages733-759
Number of pages27
ISBN (Print)9781846288531
DOIs
StatePublished - 2008

Fingerprint

Anti-Arrhythmia Agents
Sudden Death
Sudden Cardiac Death
Incidence
Out-of-Hospital Cardiac Arrest
Ambulatory Electrocardiography
Hypertrophic Cardiomyopathy
Dilated Cardiomyopathy
Ventricular Fibrillation
Ventricular Tachycardia
North America
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lee, H. C. (2008). Clinical role of antiarrhythmic drugs in the prevention of sudden death. In Electrical Diseases of the Heart: Genetics, Mechanisms, Treatment, Prevention (pp. 733-759). Springer London. https://doi.org/10.1007/978-1-84628-854-8_53

Clinical role of antiarrhythmic drugs in the prevention of sudden death. / Lee, Hon Chi.

Electrical Diseases of the Heart: Genetics, Mechanisms, Treatment, Prevention. Springer London, 2008. p. 733-759.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lee, HC 2008, Clinical role of antiarrhythmic drugs in the prevention of sudden death. in Electrical Diseases of the Heart: Genetics, Mechanisms, Treatment, Prevention. Springer London, pp. 733-759. https://doi.org/10.1007/978-1-84628-854-8_53
Lee HC. Clinical role of antiarrhythmic drugs in the prevention of sudden death. In Electrical Diseases of the Heart: Genetics, Mechanisms, Treatment, Prevention. Springer London. 2008. p. 733-759 https://doi.org/10.1007/978-1-84628-854-8_53
Lee, Hon Chi. / Clinical role of antiarrhythmic drugs in the prevention of sudden death. Electrical Diseases of the Heart: Genetics, Mechanisms, Treatment, Prevention. Springer London, 2008. pp. 733-759
@inbook{88710ab579364abb940967739f0cd112,
title = "Clinical role of antiarrhythmic drugs in the prevention of sudden death",
abstract = "Sudden cardiac death is a leading cause of mortality in the United States, but recent studies suggest that its annual incidence is declining. The annual incidence of sudden cardiac death is about 0.55 per 1000 people in North America, accounting for more than 160,000 deaths each year in the United States.1 In Seattle, there was a 34{\%} decrease in the annual incidence of out-of-hospital cardiac arrest and a 56{\%} decrease in ventricular fibrillation (VF) as the first identified rhythm between 1980 and 2000.2 This trend corresponds with the declining incidence of cardiovascular disease in this country in the past two decades.1 Holter monitoring has revealed that more than 75{\%} of sudden cardiac deaths are due to ventricular tachycardia (VT) or VF.3 A large majority of these patients have underlying structural heart disease including dilated and hypertrophic cardiomyopathies and ischemic heart disease.",
author = "Lee, {Hon Chi}",
year = "2008",
doi = "10.1007/978-1-84628-854-8_53",
language = "English (US)",
isbn = "9781846288531",
pages = "733--759",
booktitle = "Electrical Diseases of the Heart: Genetics, Mechanisms, Treatment, Prevention",
publisher = "Springer London",

}

TY - CHAP

T1 - Clinical role of antiarrhythmic drugs in the prevention of sudden death

AU - Lee, Hon Chi

PY - 2008

Y1 - 2008

N2 - Sudden cardiac death is a leading cause of mortality in the United States, but recent studies suggest that its annual incidence is declining. The annual incidence of sudden cardiac death is about 0.55 per 1000 people in North America, accounting for more than 160,000 deaths each year in the United States.1 In Seattle, there was a 34% decrease in the annual incidence of out-of-hospital cardiac arrest and a 56% decrease in ventricular fibrillation (VF) as the first identified rhythm between 1980 and 2000.2 This trend corresponds with the declining incidence of cardiovascular disease in this country in the past two decades.1 Holter monitoring has revealed that more than 75% of sudden cardiac deaths are due to ventricular tachycardia (VT) or VF.3 A large majority of these patients have underlying structural heart disease including dilated and hypertrophic cardiomyopathies and ischemic heart disease.

AB - Sudden cardiac death is a leading cause of mortality in the United States, but recent studies suggest that its annual incidence is declining. The annual incidence of sudden cardiac death is about 0.55 per 1000 people in North America, accounting for more than 160,000 deaths each year in the United States.1 In Seattle, there was a 34% decrease in the annual incidence of out-of-hospital cardiac arrest and a 56% decrease in ventricular fibrillation (VF) as the first identified rhythm between 1980 and 2000.2 This trend corresponds with the declining incidence of cardiovascular disease in this country in the past two decades.1 Holter monitoring has revealed that more than 75% of sudden cardiac deaths are due to ventricular tachycardia (VT) or VF.3 A large majority of these patients have underlying structural heart disease including dilated and hypertrophic cardiomyopathies and ischemic heart disease.

UR - http://www.scopus.com/inward/record.url?scp=84890236973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890236973&partnerID=8YFLogxK

U2 - 10.1007/978-1-84628-854-8_53

DO - 10.1007/978-1-84628-854-8_53

M3 - Chapter

AN - SCOPUS:84890236973

SN - 9781846288531

SP - 733

EP - 759

BT - Electrical Diseases of the Heart: Genetics, Mechanisms, Treatment, Prevention

PB - Springer London

ER -